Journal
CANCERS
Volume 13, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/cancers13061412
Keywords
primary liver cancer; hepatocellular carcinoma; metabolic syndrome; genetic predisposition; single-nucleotide polymorphism; PDCD1; PD-1; PNPLA3; TM6SF2
Categories
Funding
- European Community's Seventh Framework Programme (FP7/2010-2013) [HEALTH-F2-2009-241762]
- CR UK Newcastle Experimental Cancer Medicine Center award [C9380/A18084]
- CR UK programme [C18342/A23390]
- European Community's Horizon 2020 Programme (EPoS Grant) [634413]
- IMI2 (LITMUS Grant) [777377]
- European NAFLD Registry
- CR UK HUNTER Accelerator [C9380/A26813]
- Newcastle University Research Fellowship
- Ricerca Finalizzata Ministero della Salute [RF-2016-02364358]
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- European Union (EU) Programme Horizon 2020 [777377]
- Programme Photonics [101016726]
- Fondazione IRCCS Ca' Granda Ricerca corrente, Fondazione Sviluppo Ca' Granda [PR-0391, RC100017A]
- H2020 Societal Challenges Programme [634413] Funding Source: H2020 Societal Challenges Programme
Ask authors/readers for more resources
The study explores how genetic variations in immunoregulatory genes may impact the development of liver cancer in patients with NAFLD, both with and without cirrhosis. Results suggest that certain variations in genes such as PDCD1 may increase the risk of NAFLD-HCC development, independent of the presence of cirrhosis.
Simple Summary Many more people are dying each year from primary liver cancers arising in obesity-related fatty liver disease. Often these cancers are a consequence of fatty liver disease progression, with inflammation, scarring and cirrhosis. Less often, cancers develop in the presence of fat without cirrhosis. Evidence from animal models suggests the immune response to fat is important. We have explored genetic variations in candidate immunoregulatory genes. Our study of nearly one-thousand patients with fatty liver disease, comparing 391 with cancers to 594 without, indicates that genetic variation in a gene (PDCD1) that codes for the T cell receptor PD-1 may be important. Inherited variations that affect function of immunoregulatory proteins like PD-1 may underpin why some patients with fatty liver disease-whether they have cirrhosis or not-are more likely to develop liver cancer. Obesity and non-alcoholic fatty liver disease (NAFLD) are contributing to the global rise in deaths from hepatocellular carcinoma (HCC). The pathogenesis of NAFLD-HCC is not well understood. The severity of hepatic steatosis, steatohepatitis and fibrosis are key pathogenic mechanisms, but animal studies suggest altered immune responses are also involved. Genetic studies have so far highlighted a major role of gene variants promoting fat deposition in the liver (PNPLA3 rs738409; TM6SF2 rs58542926). Here, we have considered single-nucleotide polymorphisms (SNPs) in candidate immunoregulatory genes (MICA rs2596542; CD44 rs187115; PDCD1 rs7421861 and rs10204525), in 594 patients with NAFLD and 391 with NAFLD-HCC, from three European centres. Associations between age, body mass index, diabetes, cirrhosis and SNPs with HCC development were explored. PNPLA3 and TM6SF2 SNPs were associated with both progression to cirrhosis and NAFLD-HCC development, while PDCD1 SNPs were specifically associated with NAFLD-HCC risk, regardless of cirrhosis. PDCD1 rs7421861 was independently associated with NAFLD-HCC development, while PDCD1 rs10204525 acquired significance after adjusting for other risks, being most notable in the smaller numbers of women with NAFLD-HCC. The study highlights the potential impact of inter individual variation in immune tolerance induction in patients with NAFLD, both in the presence and absence of cirrhosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available